Like much of the previous research on coffee, thestudy was based on survey data -- in this case, a single questionnaire distributed in the mid-1990s -- that may provide an incomplete picture of the participants' overall health and lifestyle.
The FDA based its approval of the NovoTTF 100A System on results from a single international clinical study in 237 patients with recurrent GBM or with GBM that hadn't responded to traditional therapy.